Table 2A.
Distribution of antimicrobial resistance genes and point mutations identified in Campylobacter jejuni genomes according to their phenotypes as determined by disk diffusion testing
| Campylobacter jejuni (N = 97) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistance genes and point mutations | Quinolonesa (N = 97) | Macrolidesb (N = 97) | Tetracyclinesc (N = 97) | Aminoglycosidesd (N = 97) | Amoxicillin-clavulanic acid (N = 91) | Ampicillin (N = 57) | ||||||
| Resistant (N = 68) | Susceptible (N = 29) | Resistant (N = 16) | Susceptible (N = 81) | Resistant (N = 50) | Susceptible (N = 47) | Resistant (N = 10) | Susceptible (N = 87) | Resistant (N = 3) | Susceptible (N = 88) | Resistant (N = 27) | Susceptible (N = 30) | |
| MDR | ||||||||||||
| RE-cmeABC | 44.0% (33/68) | 6.9% (2/29) | 62.5% (10/16) | 30.9% (25/81) | 64.0% (32/50) | 6.4% (3/47) | 70.0% (7/10) | 32.0% (28/87) | 66.7% (2/3) | 35.2% (31/88) | 51.9% (14/27) | 0% (0/30) |
| Quinolones | ||||||||||||
| gyrA Thr86Ile | 75.0% (51/68) | 13.8% (4/29) | 68.8% (11/16) | 54.3% (44/81) | 82.0% (41/50) | 29.8% (14/47) | 80.0% (8/10) | 54.0% (47/87) | 66.7% (2/3) | 62.5 (51/88) | 55.6% (15/27) | 33.3% (10/30) |
| Macrolides | ||||||||||||
| 23S rRNA A2075G | 7.4% (5/68) | 3.5% (1/29) | 31.3% (5/16) | 1.2% (1/81) | 12.0% (6/50) | 0% (0/47) | 0% (0/10) | 11.5% (10/87) | 0% (0/3) | 6.8% (6/88) | 18.5% (5/27) | 0% (0/30) |
| Tetracyclines | ||||||||||||
| tet(O) | 57.4% (39/68) | 17.2% (5/29) | 68.8% (11/16) | 40.7% (33/81) | 76.0% (38/50) | 12.8% (6/47) | 90.0% (9/10) | 40.2% (35/87) | 66.7% (2/3) | 45.5% (40/88) | 55.6% (15/27) | 6.7% (2/30) |
| Aminoglycosides | ||||||||||||
| Any gene | 32.4% (22/68) | 6.9% (2/29) | 12.5% (2/16) | 27.2% (22/81) | 42.0% (21/50) | 6.4% (3/47) | 70.0% (7/10) | 19.5% (17/87) | 33.3% (1/3) | 23.9% (21/88) | 3.7% (1/27) | 0% (0/30) |
| aph(2′)-If | 13.2% (9/68) | 0% (0/29) | 6.3% (1/16) | 9.9% (8/81) | 18.0% (9/50) | 0% (0/47) | 60.0% (6/10) | 3.5% (3/87) | 0% (0/3) | 8.0% (7/88) | 0% (0/27) | 0% (0/30) |
| aph(3′)-IIIa | 33.3% (20/68) | 6.9% (2/29) | 6.3% (1/16) | 25.9% (21/81) | 38.0% (19/50) | 6.4% (3/47) | 60.0% (6/10) | 18.4% (16/87) | 33.3% (1/3) | 21.6% (19/88) | 0% (0/27) | 0% (0/30) |
| aad6 | 1.5% (1/68) | 0% (0/29) | 0% (0/16) | 1.2% (1/81) | 2.0% (1/50) | 0% (0/47) | 0% (0/10) | 1.1% (1/87) | 0% (0/3) | 1.1% (1/88) | 0% (0/27) | 0% (0/30) |
| aad9 | 30.9% (21/68) | 6.9% (2/29) | 6.3% (1/16) | 27.2% (22/81) | 40.0% (20/50) | 6.4% (3/47) | 70.0% (7/10) | 18.4% (16/87) | 33.3% (1/3) | 22.7% (20/88) | 0% (0/27) | 0% (0/30) |
| aadE | 19.1% (13/68) | 6.9% (2/29) | 0% (0/16) | 18.5% (15/81) | 24.0% (12/50) | 6.4% (3/47) | 10% (1/10) | 16.1% (14/87) | 33.3% (1/3) | 14.8% (13/88) | 0% (0/27) | 0% (0/30) |
| ant6-Ia | 20.6% (14/69) | 6.9% (2/29) | 0% (0/16) | 19.8% (16/81) | 26.0% (13/50) | 6.4% (3/47) | 10% (1/10) | 17.2% (6/87) | 33.3% (1/3) | 7.8% (14/88) | 0% (0/27) | 0% (0/30) |
| SAT4 | 1.5% (1/68) | 0% (0/29) | 0% (0/16) | 1.2% (1/81) | 2.0% (1/50) | 0% (0/47) | 10% (1/10) | 1.1% (1/87) | 0% (0/3) | 1.1% (1/88) | 0% (0/27) | 0% (0/30) |
| rpsL | 1.5% (1/68) | 0% (0/29) | 6.3% (1/16) | 0% (0/81) | 2.0% (1/50) | 0% (0/47) | 0% (0/10) | 1.1% (1/87) | 0% (0/3) | 1.1% (1/88) | 3.7% (1/27) | 0% (0/30) |
| Beta-lactams | ||||||||||||
| blaOXA genee | 73.5% (50/68) | 37.9% (11/29) | 75.0% (12/16) | 60.5% (49/81) | 86.0% (43/50) | 38.3% (18/47) | 80.0% (8/10) | 60.9% (53/87) | 66.7% (2/3) | 62.5% (55/88) | 74.1% (20/27) | 30.0% (9/30) |
| Active TATA boxf | 55.9% (38/68) | 17.2% (5/29) | 50.0% (8/16) | 43.2% (35/81) | 74.0% (37/50) | 12.8% (6/47) | 80.0% (8/10) | 40.2% (35/87) | 66.7% (2/3) | 42.0% (37/88) | 48.1% (13/27) | 3.3% (1/30) |
NOTE: Other mutations in the gyrA gene (Asp90Asn, Thr86Lys, Thr86Val, Thr86Ala and Asp90Tyr substitutions, and double mutations Thr86Ile-Pro104Ser and Thr86Ile-Asp90Asn), 23S rRNA genes (A2074G, A2075C), mutations in L4 and L22 ribosomal proteins, and ermB resistance gene were not found. bolded = resistance genes associated with phenotypic profile MDR, multidrug-resistant.
Includes susceptibility to CIP.
Includes susceptibility to AZM and ERY.
Includes susceptibility to TET.
Includes susceptibility to GEN.
All blaOXA genes belong to the blaOXA61 and blaOXA184 family.
G to T transversion represents an activation of the TATA box.